Kymera Investor Presentation Deck

As of the data cut-off of May 1, 2023: PK and PD profiles in DL1-3* consistent with preclinical data ● Desired Translation of PK, PD and Safety of KT-333 Proof-of-mechanism for KT-333 demonstrated with up to 88% mean max degradation of STAT3 in peripheral blood mononuclear cells. ● This profile is nearing 90% target degradation that led to robust antitumor activity in STAT3-driven preclinical tumor models. • The most common adverse events were Grade 1 and 2 and included fatigue and gastrointestinal symptoms, with no DLTs observed or drug related SAEs. Expect to be at potentially clinically active exposures at DL4 and beyond. *DL1-3 have been completed and DL4 remains open to accrual. KYMERA ©2023 KYMERA THERAPEUTICS, INC. First-in-class Opportunity to Address STAT3-driven Pathology Across Diverse Indications First heterobifunctional degrader against an undrugged target in the clinic Clinical development strategy includes monotherapy direct registrational path in STAT3 dependent T cell malignancies Opportunity for expansion into solid tumors in combination with immune checkpoint inhibitors informed by planned analysis of PDL1 and TME markers in solid tumor sample from ongoing trial PAGE 49

View entire presentation